Starting ADCs for HR+/HER2- Metastatic Breast Cancer

First, a Quick Reality Check: HR+/HER2- MBC Isn’t One “Lane”

HR+/HER2- metastatic breast cancer is often treated as a long game. Many people start with endocrine therapy (hormone-blocking treatment) plus targeted medicines
(commonly CDK4/6 inhibitors), because that combo can control disease while preserving quality of life for many patients.

Over time, cancer can become less responsive to hormone-based approaches, or a person may need treatment that works faster because of symptoms or organ involvement.
That’s when treatment plans often shift toward chemotherapy, newer targeted therapies (depending on tumor markers), and nowmore often than everADCs.

The big idea: “HER2-negative” is no longer the whole story. Some tumors have low or ultralow levels of HER2 expression that still matter for treatment selection,
even though they aren’t HER2-positive in the classic sense. That nuance can open the door to certain HER2-directed ADCs.

What Exactly Is an ADC (and Why Is Everyone Excited)?

An ADC has three main parts:

• The antibody: seeks out a target on (or near) cancer cells.
• The linker: a chemical “clip” designed to hold the payload until it reaches the target.
• The payload: a chemotherapy-like drug, often very potent, meant to damage cancer cells once delivered.

Think of it like a package delivery with tracking. Traditional chemo is more like a neighborhood sprinklers system:
effective, but it can also water the driveway and the dog. ADCs aim to be more selectivethough they’re not side-effect-free.

For HR+/HER2- MBC, ADCs are especially important because they can provide meaningful benefit after hormone therapies and other systemic treatments have already been used.

The ADC Lineup for HR+/HER2- Metastatic Breast Cancer

In the U.S., three ADCs are commonly discussed for HR+/HER2- metastatic breast cancer. Each has its own “sweet spot,” eligibility requirements,
and side-effect personality (yes, drugs have personalitiessome are needy, some are dramatic, and some are both).

1) Trastuzumab deruxtecan (T-DXd)

This is a HER2-directed ADC. The key is that it can be used in certain cases of HR+ metastatic breast cancer that are
HER2-low (often defined as IHC 1+ or IHC 2+ with a negative ISH/FISH test) or HER2-ultralow (very minimal expression).
If your pathology report has ever made you feel like you need a decoder ring, you’re not alone.

When it may come up: typically after disease progression on endocrine therapy, and often after at least some prior systemic treatment.
Your oncologist may also consider how quickly disease is progressing and what treatments you’ve already received.

Big watch-outs: one of the most important risks with T-DXd is interstitial lung disease (ILD)/pneumonitis.
That’s why your team may ask about cough, shortness of breath, oxygen levels, and may monitor lung symptoms closely.

2) Sacituzumab govitecan (SG)

Sacituzumab govitecan is a TROP2-directed ADC (TROP2 is a protein commonly found on many breast cancer cells). In HR+/HER2- metastatic disease,
it’s generally considered after endocrine therapy and other systemic treatments have been used.

When it may come up: commonly after prior endocrine therapy (including CDK4/6 inhibitors) and after multiple prior lines of chemotherapy
in the metastatic setting (exact sequencing varies by patient and evolving practice).

Big watch-outs: low white blood cell counts (especially neutropenia) and diarrhea are well-known issues.
The good news is your care team has playbooks for bothlabs and growth-factor support for counts, and anti-diarrheal plans when needed.

3) Datopotamab deruxtecan (Dato-DXd)

Datopotamab deruxtecan (brand name DATROWAY) is another TROP2-directed ADC, and its U.S. approval created a new option for previously treated
HR+/HER2- metastatic breast cancer.

When it may come up: after prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease.
In real-world decision-making, doctors may weigh Dato-DXd alongside other ADCs, especially when considering side-effect profiles and prior exposure.

Big watch-outs: Dato-DXd is associated with side effects like mouth sores (stomatitis), eye-related issues (including keratitis),
and a risk of ILD/pneumonitis (a theme you’ll notice with some “deruxtecan” payload ADCs).

Step Zero: Confirm You’re a Match (Testing That Actually Matters)

Starting an ADC is not just “pick a drug, book an infusion chair.” Eligibility and sequencing depend on details that sometimes require a second look:

• HER2 testing details: If T-DXd is on the table, your oncologist may review your HER2 immunohistochemistry (IHC) score carefully.
  Sometimes a metastatic biopsy is considered, because HER2 expression can differ between the original tumor and metastatic sites.
• Prior treatments: Many ADC indications depend on prior endocrine therapy and/or prior chemotherapy exposure.
  Your treatment history is basically your cancer’s résuméand ADCs often have “required experience” sections.
• Baseline health checks: Blood counts, liver function, kidney function, and symptom history matter because they affect safety and dosing.

If you’re thinking, “Cool, so my tumor has a score now,” you’re not wrong. But it’s a score with real consequences: it can unlockor rule outcertain treatments.

Your Pre-Start “ADC Checklist” (Practical, Not Theoretical)

Here’s what many patients find helpful to cover before starting an ADC. Your oncologist may not use this exact checklist,
but these are the themes that tend to show up in real clinics.

Medical prep

• Review symptoms: new cough, shortness of breath, fevers, diarrhea, appetite changes, numbness/tingling, vision changes, mouth soreness.
• Discuss lung history: asthma, COPD, pulmonary fibrosis, prior chest radiation, or prior drug-related lung issues can influence monitoring plans.
• Confirm supportive meds: anti-nausea meds, anti-diarrheals, mouth-rinse strategies, and any growth-factor plan (if needed).
• Ask about vaccines and infection prevention: because some ADCs can lower white blood cells.

Life prep (yes, it matters)

• Infusion logistics: how long it takes, how often you’ll come in, and whether you’ll need a driver the first time.
• Work/family planning: fatigue can be realplan lighter days around infusion, if possible.
• Food strategy: keep easy proteins, bland snacks, and hydration options on standby.
• Symptom tracking: a notes app works. So does a sticky note on your fridge. The best system is the one you’ll actually use.

What the First Infusion Day Usually Feels Like

On day one, most people discover two truths:
(1) infusion centers are staffed by people who can start an IV while talking about weekend plans, and
(2) the chair is more comfortable than your kitchen chair, which is unfair.

Most ADCs are given through an IV infusion. You’ll typically have labs checked regularly to ensure blood counts and organ function are in a safe range.
You may receive pre-meds to reduce nausea or infusion reactions, depending on the drug and your history.

The first cycle is often a “data-gathering” cycle: your team learns how your body responds, and you learn which side effects you personally get.
(Because treatments never read the same script for everyoneunfortunately.)

Side Effects: The Stuff People Actually Want to Know

ADCs are targeted, but the payload is still a chemo-like agent. Side effects are common, and serious side effects are possible.
The goal is not to “tough it out”it’s to catch problems early and adjust quickly.

Common side effects across many ADCs

• Fatigue: often cumulative. Hydration, light movement, and realistic scheduling help.
• Nausea: can range from mild to “why do smells exist?”antiemetics and timing meals matter.
• Low blood counts: especially neutropenia with some ADCs, raising infection risk.
• Hair thinning or hair loss: varies by drug and person.
• GI changes: diarrhea or constipation, appetite changes.

Drug-specific “pay attention now” risks

• ILD/pneumonitis (especially with T-DXd and some deruxtecan-based ADCs):
  report new cough, shortness of breath, chest tightness, or unexplained fever promptly. Early evaluation can be critical.
• Diarrhea (notably with sacituzumab govitecan):
  don’t wait until you’re dehydratedask your team for a specific plan the first time symptoms appear.
• Mouth sores/stomatitis (commonly discussed with Dato-DXd):
  starting preventive mouth care early can make a big difference in comfort and nutrition.
• Eye symptoms (Dato-DXd):
  new eye pain, redness, blurred vision, or light sensitivity should be reportedyour team may recommend eye care strategies or referral.

A helpful mindset: side-effect management is not “optional DLC.” It’s part of the treatment. The sooner you report symptoms, the more options your team has
(dose adjustments, timing changes, supportive meds, brief holds, or specialist input).

Choosing Which ADC to Start: How Clinicians Often Think About It

There isn’t one universal sequence for every person with HR+/HER2- metastatic breast cancerbecause the disease and the patient are both variable.
Still, certain patterns show up in real clinical decision-making:

• HER2-low or ultralow status: If the cancer qualifies, a HER2-directed ADC like T-DXd may be considered because of demonstrated benefit in that subgroup.
• Prior therapies: Some ADCs are used after multiple prior treatments; others may be considered earlier depending on label criteria, symptoms, and practice patterns.
• Comorbidities and risk tolerance: Lung history may influence comfort with ILD risk; baseline GI issues may influence diarrhea risk planning.
• Quality-of-life priorities: Work schedule, caregiving responsibilities, travel distance to infusion centers, and symptom burden all matter.

A concrete example: two patients may both be HR+/HER2- metastatic, but one has HER2-low disease and minimal lung history, while the other has borderline lung function
and severe baseline diarrhea from prior therapy. The “best” ADC choice could look differenteven before you consider tumor behavior and response history.

Can You Take More Than One ADC Over Time?

This is a common question, and the honest answer is: sometimes, but it’s complicated. Researchers are actively studying sequencing and outcomes when patients receive
one ADC followed by another. In practice, oncologists may consider sequential ADC use based on what a patient has already received, how they tolerated it,
and whether the next ADC has a different target and side-effect profile.

If this is relevant to you, it’s worth asking your oncologist two very specific questions:

• “What would we use next if this ADC stops working?”
• “If we’re thinking about another ADC later, does that change which one we should choose first?”

And yesclinical trials may be part of this conversation. Trials are not a “last resort”; they’re often how patients access tomorrow’s standard treatments today.

Questions to Ask Before You Start (Steal These)

• Eligibility: “What makes me a candidate for this ADC?”
• Testing: “Do we need to re-check HER2 on a metastatic biopsy or review my pathology?”
• Schedule: “How often are infusions, and how long does each visit take?”
• Monitoring: “What labs or scans will we use to watch for side effects like low blood counts or lung inflammation?”
• Symptoms: “What side effects should trigger a same-day call?”
• Support meds: “Can we plan anti-nausea, diarrhea prevention, and mouth-care strategies in advance?”
• Plan B: “If I don’t tolerate this, what are our next options?”

Conclusion: Starting an ADC Is a Strategy, Not a Surprise

For HR+/HER2- metastatic breast cancer, ADCs have become a major part of modern treatmentnot because they’re trendy, but because they can work after other therapies
stop doing their job. Starting an ADC usually involves (1) confirming tumor characteristics like HER2-low/ultralow status when relevant, (2) reviewing prior therapies,
(3) building a monitoring and side-effect plan that matches the drug’s known risks, and (4) aligning the treatment schedule with real life.

If you remember just one thing: you’re not “being difficult” by asking detailed questions. You’re being strategic.
ADCs are powerful toolsyour job is to start them with eyes open and a plan in your pocket.

Medical note: This article is educational and not a substitute for individualized medical advice. Your oncology team can tailor recommendations to your specific situation.

Real-World Experiences: What Starting an ADC Can Feel Like

People often expect the first ADC infusion to feel like a dramatic movie scene: alarms, plot twists, emotional background music. In reality, it’s usually quieter
a mix of paperwork, warm blankets, and the odd moment where you realize you’ve become the kind of person who has opinions about vein quality.
Many patients describe the “starting” phase as less about the infusion itself and more about learning the rhythm afterward.

One common experience is the mental shift from hormone-based therapyoften pills or injections that become part of routineto an IV treatment that turns your calendar
into a color-coded masterpiece. Some people feel relieved because the plan is clear: “I go in, I get treatment, we track results.” Others feel anxious because
IV therapy can sound more intense, even when it’s the right next step. Both reactions are normal, and many patients report that anxiety often eases after cycle one
because the unknown becomes known.

Side effects can be surprisingly individualized. Two people can be on the same ADC and have completely different “main characters” in their symptom story.
Some say nausea is their biggest hurdlebut improves dramatically when anti-nausea medication is adjusted early. Others describe fatigue as the slow-burn side effect:
not a crash on day one, but a cumulative heaviness that shows up after a couple of cycles. A frequent tip from patients is to plan a “recovery buffer” day after infusion,
even if you feel fine at first. It’s like packing an umbrella when the forecast says 10% rainmaybe you won’t need it, but you’ll feel smug if you do.

People starting deruxtecan-based ADCs often talk about becoming more attentive to breathing changes than they ever were before. That doesn’t mean living in fear;
it means getting comfortable with quick check-ins: “Is this a normal cold? Am I winded doing something easy? Is this new?” Patients who feel empowered tend to have a
simple rule: report early, don’t self-diagnose. They’re not trying to win an award for endurancethey’re trying to stay on an effective therapy safely.

Practical comfort strategies come up again and again: keeping a symptom diary, stocking easy foods for low-appetite days, carrying snacks to infusions,
and setting phone reminders to hydrate. People who deal with mouth sores often become unexpectedly passionate about gentle oral care and avoiding spicy or acidic foods
during flare-ups (goodbye, salsatemporarily). Those who experience diarrhea often say the best advice they got was not to wait: call early, treat early, hydrate early.

Finally, there’s the emotional part: starting an ADC can feel like a marker“we’re moving to the next phase.” Many patients describe it as both sobering and hopeful.
Sobering because metastatic treatment is continuous; hopeful because ADCs represent meaningful progress and more options than existed not long ago.
If you’re starting an ADC, it’s okay to feel two things at once. That’s not confusion. That’s being human.